What orforglipron is
Orforglipron is a once-daily oral GLP-1 receptor agonist developed by Eli Lilly. Like injectable semaglutide and liraglutide, it activates the receptor for glucagon-like peptide-1, a gut hormone that reduces appetite and improves blood sugar control. Unlike those drugs, orforglipron is a small molecule rather than a peptide. That allows it to be taken as a pill, and Lilly states it can be taken without food or water restrictions (company-reported).
Regulatory status
| Use | Status |
|---|---|
| Chronic weight management (adults with obesity, or overweight with weight-related conditions) | FDA-approved as Foundayo, April 1, 2026 (NDA 220934) |
| Type 2 diabetes | Submitted in the U.S. (company-reported, August 2026); not yet approved |
| Cardiovascular outcomes and other conditions | In Phase 3 trials |
The FDA approved Foundayo under its Commissioner's National Priority Voucher pilot program. In its announcement, the FDA described it as the first new molecular entity approved under the program and the fastest approval of a new molecular entity since 2002, coming 50 days after filing. The label includes a boxed warning for thyroid C-cell tumors, as do other drugs in the class.
Clinical evidence
Obesity: ATTAIN-1
ATTAIN-1 randomized 3,127 adults with obesity, or overweight with a weight-related condition, and no diabetes. Published in the New England Journal of Medicine in 2025, mean changes in body weight at 72 weeks were:
| Dose | Change in body weight |
|---|---|
| 6 mg | −7.5% |
| 12 mg | −8.4% |
| 36 mg | −11.2% |
| Placebo | −2.1% |
On 36 mg, 54.6% of participants lost at least 10% of their body weight, compared with 12.9% on placebo. Adverse events led to discontinuation in 5.3% to 10.3% of orforglipron groups, compared with 2.7% with placebo. The most common adverse events were gastrointestinal and mostly mild to moderate, consistent with other GLP-1 receptor agonists.
Type 2 diabetes: ACHIEVE
In ACHIEVE-1, published in the New England Journal of Medicine in 2025, 559 people with early type 2 diabetes and a mean glycated hemoglobin (HbA1c) of 8.0% were randomized. At 40 weeks, HbA1c fell by 1.24 to 1.48 percentage points with orforglipron, compared with 0.41 with placebo. All doses were superior to placebo. ACHIEVE-3, published in The Lancet in 2026, compared orforglipron with oral semaglutide. Lilly has reported that the ACHIEVE program supported a U.S. submission for type 2 diabetes.
Scientific perspective
Orforglipron's significance is less about magnitude than about format. Its weight loss in ATTAIN-1 is smaller than that reported for injectable tirzepatide or for retatrutide, but a once-daily pill without dosing restrictions could make GLP-1 therapy easier to start, scale, and manufacture. Small molecules are generally simpler to produce at large volumes than peptides.
The key scientific questions now are long-term: cardiovascular outcomes, which a 7,140-participant outcomes trial is testing, and real-world persistence, since daily oral therapy depends on patients continuing to take it.
Development perspective
- Approved use: chronic weight management. Benchmarks are not shown for this program because it is already approved.
- Type 2 diabetes: submitted (company-reported). Historically, 90.6% of applications that reached the FDA were eventually approved, often after resubmission. That is an industry-wide figure and not a prediction for this application.
- Cardiovascular safety: Lilly reported in October 2026 that orforglipron demonstrated cardiovascular safety (company-reported). The detailed results had not been peer-reviewed in the sources we reviewed.
- Speed of approval: the 50-day review under the National Priority Voucher pilot is unusual. Standard reviews for new molecular entities target about 12 months from submission. See How Does the FDA Approve New Drugs?
Competitive context
Foundayo enters a market led by injectable semaglutide and tirzepatide, and competes with oral semaglutide. Its advantages are convenience and potentially manufacturing scale. Its trade-off, based on published trials, is more modest average weight loss than the leading injectables.
Development timeline
- Jun 5, 2023ATTAIN-1 Phase 3 obesity trial begins. Registry
- Jun 21, 2025ACHIEVE-1 published: glycated hemoglobin fell by up to 1.48 points at 40 weeks in early type 2 diabetes. Peer-reviewed
- Sep 16, 2025ATTAIN-1 published: −11.2% body weight at 72 weeks on 36 mg, versus −2.1% with placebo. Peer-reviewed
- Feb 26, 2026ACHIEVE-3 published: orforglipron compared with oral semaglutide in type 2 diabetes. Peer-reviewed
- Apr 1, 2026FDA approves Foundayo (orforglipron) for chronic weight management under the National Priority Voucher pilot program. Regulator
- Aug 5, 2026Lilly reports a U.S. regulatory submission for orforglipron in type 2 diabetes. Company-reported
- Oct 29, 2026Lilly reports that orforglipron demonstrated cardiovascular safety. Company-reported
What could change the outlook
- The FDA decision on the type 2 diabetes submission.
- Peer-reviewed publication of the cardiovascular safety results Lilly reported in October 2026.
- The 7,140-participant cardiovascular outcomes trial, which could support a cardiovascular risk-reduction claim (registry estimates primary completion in August 2031).
- Real-world tolerability and persistence, since gastrointestinal effects led some trial participants to discontinue.
- Additional submissions for weight-related conditions, such as obstructive sleep apnea.
Latest company disclosures
Company press releases (SEC filings and PR Newswire) that mention Orforglipron. Company-reported, not independently verified.
- Quarterly reportCompany-reportedOct 29, 2026
Lilly reports third-quarter 2026 financial results, raises full-year guidance and highlights regulatory progress across the portfolio
“Revenue growth was driven by broad global consumer demand for Mounjaro and Zepbound, the global launches of Foundayo, expanded U.S. coverage for obesity care and a doubling in our newest products in oncology, immunology and neuroscience.
- Trial resultsCompany-reportedOct 1, 2026
Lilly's oral GLP-1, Foundayo (orforglipron), was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease
Eli Lilly and Company (NYSE: LLY ), the maker of Zepbound (tirzepatide), today announced results from post-hoc analyses of ATTAIN-1 showing that Foundayo was associated with significant reductions in predicted 10-year risk of type 2 diabetes and cardiovascular disease in adults with obesity or overweight with a...
- Trial resultsCompany-reportedSep 30, 2026
Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study
Eli Lilly and Company (NYSE: LLY ), the maker of Zepbound (tirzepatide), today announced detailed results from the Phase 3 ACHIEVE-4 trial evaluating the efficacy and safety of Foundayo (orforglipron) compared to titrated insulin glargine in adults with type 2 diabetes and obesity or overweight at increased...